Latest Institutional Placement News

DXN Limited has secured A$7 million from institutional investors to fund delivery of its maiden AI HPC modular data centre contract and expand manufacturing capacity in Southeast Asia.

Peninsula Energy has completed a fully underwritten A$36.1 million equity raising, supplemented by a US$30 million convertible debt facility, bolstering its financial firepower as it ramps up uranium production at its Lance Project.

Lindian Resources has cancelled 13 million performance rights held by a former executive chairman, sparking uncertainty as a potential $10 million claim looms.

EBR Systems has secured A$106.4 million through a fully underwritten institutional placement and entitlement offer, positioning the company for further commercial expansion of its wireless cardiac pacing technology.

Tetratherix Limited (ASX:TTX) has launched a $2 million share purchase plan offering eligible Australian and New Zealand shareholders the chance to buy shares at a 2% discount to recent trading prices. The non-underwritten SPP opens on 4 June and closes on 18 June 2026.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Arafura Rare Earths has officially opened its share purchase plan following ASIC lodgement, while also dispatching notices for a July extraordinary general meeting in Perth.

Barton Gold has raised $25.5 million through an institutional placement, fully funding critical feasibility studies and resource upgrades across its Challenger, Tunkillia, and Tolmer projects in South Australia.

BluGlass has locked in a $1 million firm commitment through an option shortfall agreement, with potential to raise $1.5 million, reinforcing its financial position after an upsized $8 million placement. The funds will accelerate GaN laser contract delivery and working capital.

Findi Limited surged revenue by 36% to $83 million for FY26 but posted a hefty $52.6 million net loss, weighed down by integration costs and capital delays. The company completed a major consolidation of its Indian financial infrastructure assets and secured $25 million in fresh capital to support growth and liquidity.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Arafura Rare Earths has successfully completed the first tranche of its A$350 million placement, issuing 675.1 million shares and raising approximately A$175.5 million before costs. The second tranche awaits shareholder approval.